New Preregistration Launched at ResearchHub

Advancing Patient-Centered Precision Medicine through Open Science

On June 30, Dr. Qingyu Luo, President of One Patient One Cure, officially launched a preregistration at ResearchHub titled:
“Real-World Validation of Big-Omics-Powered AI Drug Sensitivity Predictor for Acute Myeloid Leukemia Treatment.”

This preregistered study aims to validate the real-world effectiveness of One Patient One Cure’s AI model under development, CureCancer, which predicts drug sensitivity in acute myeloid leukemia (AML). Crucially, the AI model will be tested in patient-derived xenograft (PDX) models—an essential step in demonstrating clinical relevance and translational potential.

🎯 Mission-Aligned Innovation

One Patient One Cure was founded in 2025 with the conviction that every cancer patient deserves truly individualized care. By harnessing the power of AI and multi-omics data, the nonprofit is spearheading a new era of accessible, effective, and affordable precision cancer treatment for all.

ResearchHub shares a complementary vision—accelerating scientific discovery by promoting transparency, collaboration, and reproducibility. Its platform empowers researchers to publish, critique, and fund preregistered studies, rewarding meaningful scientific contributions through ResearchCoin (RSC).

This preregistration exemplifies both missions: a bold scientific initiative grounded in transparency and community engagement. All resulting data, methodologies, and AI predictions will be shared openly, advancing collective progress in cancer precision medicine.

🤝 Joint Call for Participation from Research Leaders

To support this preregistration, Dr. Qingyu Luo, co-founder of One Patient One Cure and Associate Editor at ResearchHub, announced he will personally match all donations made by ResearchHub reviewers who contribute their peer review bounties during July.

In a powerful show of support, Patrick Joyce, co-founder and Chief Operating Officer of ResearchHub, has pledged to match those donations again—doubling the impact of any contribution made by ResearchHub reviewers. This joint effort enables a 2X match for all qualified donations.

🔬 Active Support from the Scientific Community

Dr. Xiaosheng Tan, a researcher at Rutgers University, provided a full-score review of the preregistration and emphasized the project’s innovation, rigor, and real-world applicability:

“This is a highly important approach that leverages existing omics datasets and the power of AI in handling big data to benefit not only scientific research, but more importantly, real-world cancer treatment,” said Dr. Tan in his public review.

Arty AI, ResearchHub’s experimental AI peer reviewer, also highly endorsed the proposal, stating:

“In summary, this proposal is highly promising and well-aligned with the goals of advancing precision medicine and open science.”

🌍 A Shared Vision for Impact

Together, One Patient One Cure and ResearchHub are building a powerful alliance—uniting the principles of open science with the urgent need for patient-centered, personalized cancer care. This preregistration represents not just a scientific milestone, but a call to action for all who believe in a more equitable and effective future for medicine.

🔗 View or support the preregistered study here:
https://www.researchhub.com/fund/4210/real-world-validation-of-big-omics-powered-ai-drug-sensitivity-predictor-for-acute-myeloid-leukemia-treatment